Alliance Bio-Products, Inc. Comments on Emerging Plastic Production Market Opportunity for CTS Process

The Company's Patented Cellulose-to-sugar Process Provides Dual Benefits for Cost-effective Creation and the Elimination of Petroleum

WEST PALM BEACH, FL / ACCESSWIRE / August 1, 2017 / Alliance Bio-Products, Inc. (Bio-Products), a subsidiary of Alliance BioEnergy Plus, Inc. ALLM, today commented on a recent study highlighting the emerging market opportunity within the bioplastics production industry for the company's patented cellulose to sugar (CTS) technology.

A recent study published in Science Advances indicated that humans have created 8.3 billion metric tons of plastics since the early 1950s, of which 6.3 billon tons have already become waste, with 79% of that waste accumulating in landfills or the natural environment. The tonnage of plastic waste is expected to grow as petroleum-based polymer plastic, which utilizes on average 200,000 barrels of oil a day to produce, can take up to 500 years to degrade in a landfill. Furthermore, these plastics are difficult to recycle, as each type requires specific type of processing and should not be burned due to the release of toxic chemicals.

Alliance Bio-Products' patented CTS technology provides a cost-effective solution for the production of eco-friendly bioplastics due to it's ability to convert cellulosic waste material into sugars. These sugars can then be used to create Polylactide Acid which releases 70% fewer greenhouse gases while degrading, compared to petroleum-based polymers.

The use of cellulosic sugars shortens the decomposition period of bioplastics from centuries to weeks, creating more space in landfills and limiting the impact on the environment due to its compostability. The use of existing waste within the CTS process for the creation of these bioplastics further aids in reducing CO2 emissions from the landfills.

"The need to eliminate the amount of waste accumulating across the globe has created a new opportunity for the wide-scale production of eco-friendly, bioplastics," said Jim Brown, President of Alliance Bio-Products. "As manufacturers and environmental agencies alike work together to identify a solution to minimize our plastic footprint, we expect to see increased adoption of our CTS technology which eliminates existing waste piling up in landfills and also minimizes future waste due to its ability to degrade in a shorter time-span."

To further the commercialization of its CTS technology, the Company recently announced a funding opportunity through a 506(c) filing to raise $10 million for the purchase of a closed biofuel facility in Florida. For more information on that opportunity, please visit the offering page.

For more information on Alliance Bio-Products, Inc., please visit its website.

About Alliance Bio-Products, Inc.

Alliance Bio-Products, Inc. was formed as a special purpose wholly-owned subsidiary of Alliance BioEnergy Plus, Inc. ("ALLM") to own and operate Bioethanol plants in the United States.

Utilizing ALLM's patented CTS process Alliance intends to retrofit existing ethanol plants with the mechnocatalytic cellulosic conversion process, transforming them into profitable renewable energy centers that are carbon neutral, waste free and protecting our delicate environment while providing energy and high value co-products. The CTS process enjoys a family of patents centered around the main U.S. patent # 8,062,428. 2032.

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The risks, uncertainties and other factors are more fully discussed in the Company's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Alliance BioEnergy Plus, Inc herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Alliance BioEnergy Plus, Inc. disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

Media contact:

Kate Caruso-Sharpe
FischTank Marketing and PR
kate@fischtankpr.com

IR Contact:

Michael Porter
Matthew Abenante
Porter LeVay & Rose Inc
7 Penn Plaza
New York, NY 10001
mike@plrinvest.com
212-564-4700

SOURCE: Alliance Bio-Products, Inc.